Investor Alert

New York Markets Close in:

Market Pulse Archives

May 4, 2022, 6:48 a.m. EDT

Regeneron shares up 1.4% premarket after earnings top estimates

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Regeneron Pharmaceuticals Inc. (REGN)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Regeneron Pharmaceuticals Inc. shares /zigman2/quotes/203149337/composite REGN -1.26% rose 1.4% in premarket trade Wednesday, after the company beat consensus estimates for the first quarter. The company posted net income of $974 million, or $8.61 a share, for the quarter, down from $1.115 billion, or $10.09 a share, in the year-earlier period. Adjusted per-share earnings came to $11.49, ahead of the $9.68 FactSet consensus. Revenue rose 17% to $2.965 billion from $2.529 billion a year ago, also ahead of the $2.690 billion FactSet consensus. "We continued to see substantial U.S. sales growth for EYLEA and Dupixent worldwide," Chief Executive Leonard S. Schleifer said in a statement. "We are well-positioned to reach even more patients with type 2 inflammatory disease through FDA priority review designations for Dupixent in children with atopic dermatitis and in adults and adolescents with eosinophilic esophagitis." Regeneron is expecting the FDA to make a decision on data submitted for REGEN-COV, a treatment for COVID in in non-hospitalized patients and as prophylaxis in certain individuals, on July 13. Shares have gained 4.6% in the year to date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.17% has fallen 12%.

US : U.S.: Nasdaq
$ 604.76
-7.73 -1.26%
Volume: 281,732
June 27, 2022 2:41p
P/E Ratio
Dividend Yield
Market Cap
$67.28 billion
Rev. per Employee
-6.76 -0.17%
Volume: 1.30B
June 27, 2022 2:41p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.